KENILWORTH, N.J., Aug.

KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S.

KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ASMANEX TWISTHALER (mometasone furoate dry powder inhaler) for the treatment of bronchial asthma in adults.(1) "We are pleased to announce the approval of the ASMANEX TWISTHALER in Japan," said Thomas P.

Schering-Plough Assumes Exclusive Worldwide Marketing Rights for Mometasone Furoate/Formoterol Combination for Asthma and COPD KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

"Don't Blow It" Online Health Game Launches; Low-Allergenic Tree Planted for Each New Player, Up to 20,000 Trees KENILWORTH, N.J., April 22 /PRNewswire/ -- Does it seem that allergy season starts earlier and there's more pollen every year? Many scientists now believe that global climate change could be partly to blame.(1) To educate people about nasal allergies and the environment, the makers of NASONEX (mometasone furoate monohydrate) Nasal Spray, 50 mcg* have teamed up with American Forests, a national tree-planting organization.